Human cytomegalovirus glycoprotein O as a new drug target...

Details Human cytomegalovirus glycoprotein O as a new drug target... Human cytomegalovirus glycoprotein O as a new drug target...

2006-12-12

2006-12-12

Housel, James (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S230100, C424S093100, C424S202100, C424S093200, C435S069100, C435S007100, C435S007800

Reexamination Certificate

active

07147861

ABSTRACT:
A method of designing a new anti-CMV drug is disclosed. In one embodiment, the invention comprises (a) analyzing the binding of glycoprotein O to a glycoprotein O receptor and (b) designing a candidate drug that would competitively interfere with glycoprotein O binding to glycoprotein O receptor and (c) showing that the candidate drug competitively inhibits glycoprotein O binding to glycoprotein O receptor. A method of screening anti-CMV drugs, a vaccine effective to diminish CMV infection, and a method of diminishing CMV infection are also disclosed.

REFERENCES:
patent: 5011829 (1991-04-01), Hirsch et al.
patent: 5149529 (1992-09-01), Ho et al.
patent: 5171568 (1992-12-01), Burke et al.
patent: 5244792 (1993-09-01), Burke et al.
patent: 5477039 (1995-12-01), Lisimaque et al.
patent: 5612041 (1997-03-01), Burke et al.
patent: 5648079 (1997-07-01), Burke et al.
patent: 5750106 (1998-05-01), Ostberg
patent: 5750114 (1998-05-01), Burke et al.
patent: 5759814 (1998-06-01), Burke et al.
patent: 5763161 (1998-06-01), Kurihara et al.
patent: 5795579 (1998-08-01), Burke et al.
patent: 5800981 (1998-09-01), Bruggeman et al.
patent: 5807557 (1998-09-01), Dubin
patent: 5837261 (1998-11-01), Inglis et al.
patent: 5853734 (1998-12-01), Chang et al.
Gretch et al. J. Virol. 1988, vol. 62, No. 3, pp. 875-881.
Huber et al. J. Virol. 1997, vol. 71, No. 7, pp. 5391-5398.
Li et al. J. Virol. 1997, vol. 71, No. 4, pp. 3090-3097.
Gonczol et al. J. Virol. 1986, vol. 58, No. 2, pp. 661-664.
Slobedman et al. Blood 2002, vol. 100, No. 100, pp. 2867-2873.
Reddehase et al. J. Clinical Virol. 2002, vol. 25 Suppl. 2, pp. s23-s36.
Gonczol et al. Exp. Opin. Biol. Ther. 2001, vol. 1(3), pp. 401-412.
Boyle, K. A., et al., “Glycoprotein B of Human Cytomegalovirus Elicits Intracellular Signaling.” (Abstract).
Huber, M. T., et al., “The HCMV UL74 Gene Encodes the Third Component of the gH/gL Complex.” (Abstract).
Huber, M. T., et al., “Characterization of a Novel Third Member of the Human Cytomegalovirus Glycoprotein H-Glycoprotein L Complex,” J. Virol., 71(7):5391-5398, 1997.
Huber, M. T., et al., “The Human Cytomegalovirus UL74 Gene Encodes the Third Component of the Glycoprotein H-Glycoprotein L-Containing Envelope Complex,” J. Virol. 72(10):8191-8197, 1998.
Huber, M. T., et al., “Intracellular Formation and Processing of the Heterotrimeric gH-gL-gO (gCIII) Glycoprotein Envelope Complex of Human Cytomegalovirus,” J. Virol. 73(5):3886-3892, 1999.
Pietropaolo, R., “Direct Interaction between Human Cytomegalovirus Glycoprotein B and Cellular Annexin II,” J. Virol. 71(12):9803-9807, 1997.

Affiliated with

Also associated with

Rating

Human cytomegalovirus glycoprotein O as a new drug target... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human cytomegalovirus glycoprotein O as a new drug target..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human cytomegalovirus glycoprotein O as a new drug target... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3687987